Skip to main content
Top
Published in: Journal of Neurology 1/2014

01-01-2014 | Original Communication

Risk factors and prodromal markers and the development of Parkinson’s disease

Authors: Stefanie Lerche, Klaus Seppi, Stefanie Behnke, Inga Liepelt-Scarfone, Jana Godau, Philipp Mahlknecht, Alexandra Gaenslen, Kathrin Brockmann, Karin Srulijes, Heiko Huber, Isabel Wurster, Heike Stockner, Stefan Kiechl, Johann Willeit, Arno Gasperi, Klaus Fassbender, Werner Poewe, Daniela Berg

Published in: Journal of Neurology | Issue 1/2014

Login to get access

Abstract

Identification of risk factors and prodromal markers for Parkinson’s disease (PD) and the understanding of the point in time of first occurrence is essential for the early detection of incident PD. In this three-center longitudinal, observational study, we evaluated the specific risk for PD associated with single or combinations of risk factors and prodromal markers. In addition, we evaluated which risk factors and prodromal markers emerge at which time before the diagnosis of PD. Of the 1,847 at-baseline PD-free individuals ≥50 years, 1,260 underwent the 5-year follow-up assessment. There were 21 cases of incident PD during the study period. Enlarged hyperechogenic substantia nigra was the most frequent baseline sign in individuals developing PD after 3 years (80.0 %) and 5 years (85.7 %) compared to healthy controls (17.5 %) followed by the occurrence of mild parkinsonian signs and hyposmia. Evaluation of the signs at the first follow-up assessment showed that individuals developing PD after two additional years showed the same pattern of signs as individuals who developed PD 3 years after baseline assessment.
Literature
1.
go back to reference Lang AE (2011) A critical appraisal of the premotor symptoms of Parkinson’s disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 26(5):775–783CrossRefPubMed Lang AE (2011) A critical appraisal of the premotor symptoms of Parkinson’s disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 26(5):775–783CrossRefPubMed
2.
go back to reference Stern MB, Lang A, Poewe W (2012) Toward a redefinition of Parkinson’s disease. Mov Disord 27(1):54–60CrossRefPubMed Stern MB, Lang A, Poewe W (2012) Toward a redefinition of Parkinson’s disease. Mov Disord 27(1):54–60CrossRefPubMed
3.
go back to reference de Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (11 Suppl 5):S21–S23 de Rijk MC, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (11 Suppl 5):S21–S23
4.
go back to reference Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ (2005) Gender and the Parkinson’s disease phenotype. J Neurol 252(10):1201–1205CrossRefPubMed Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ (2005) Gender and the Parkinson’s disease phenotype. J Neurol 252(10):1201–1205CrossRefPubMed
5.
go back to reference Siderowf A, Jennings D, Connolly J, Doty RL, Marek K, Stern MB (2007) Risk factors for Parkinson’s disease and impaired olfaction in relatives of patients with Parkinson’s disease. Mov Disord 22(15):2249–2255CrossRefPubMed Siderowf A, Jennings D, Connolly J, Doty RL, Marek K, Stern MB (2007) Risk factors for Parkinson’s disease and impaired olfaction in relatives of patients with Parkinson’s disease. Mov Disord 22(15):2249–2255CrossRefPubMed
6.
go back to reference Berg D, Seppi K, Behnke S et al (2011) Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1,847 older persons. Arch Neurol 68(7):932–937CrossRefPubMed Berg D, Seppi K, Behnke S et al (2011) Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1,847 older persons. Arch Neurol 68(7):932–937CrossRefPubMed
7.
go back to reference Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63(2):167–173CrossRefPubMed Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63(2):167–173CrossRefPubMed
8.
go back to reference Tolosa E, Compta Y, Gaig C (2007) The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 13 Suppl:S2–S7CrossRefPubMed Tolosa E, Compta Y, Gaig C (2007) The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 13 Suppl:S2–S7CrossRefPubMed
9.
go back to reference Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18(4):414–418CrossRefPubMed Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18(4):414–418CrossRefPubMed
10.
go back to reference Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldeoriola F, Tolosa E (2006) Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5(7):572–577CrossRefPubMed Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldeoriola F, Tolosa E (2006) Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5(7):572–577CrossRefPubMed
11.
go back to reference de Lau LML, Koudstaal PJ, Hofman A, Breteler MMB (2006) Subjective complaints, precede Parkinson disease—The Rotterdam study. Arch Neurol 63(3):362–365CrossRefPubMed de Lau LML, Koudstaal PJ, Hofman A, Breteler MMB (2006) Subjective complaints, precede Parkinson disease—The Rotterdam study. Arch Neurol 63(3):362–365CrossRefPubMed
12.
go back to reference Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22(12):1681–1688CrossRefPubMed Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22(12):1681–1688CrossRefPubMed
13.
go back to reference Berg D, Seppi K, Liepelt I et al (2010) Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 25(10):1464–1469CrossRefPubMed Berg D, Seppi K, Liepelt I et al (2010) Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 25(10):1464–1469CrossRefPubMed
14.
go back to reference Postuma RB, Gagnon JF (2011) Symmetry of Parkinson’s disease and REM sleep: one piece of the puzzle. Ann Neurol 69(5):905CrossRefPubMed Postuma RB, Gagnon JF (2011) Symmetry of Parkinson’s disease and REM sleep: one piece of the puzzle. Ann Neurol 69(5):905CrossRefPubMed
15.
go back to reference Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord 27(5):656–665CrossRefPubMed Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord 27(5):656–665CrossRefPubMed
16.
go back to reference Marder K, Tang MX, Mejia H et al (1996) Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology 47(1):155–160CrossRefPubMed Marder K, Tang MX, Mejia H et al (1996) Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology 47(1):155–160CrossRefPubMed
17.
go back to reference Berg D, Behnke S, Walter U (2006) Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall Med 27(1):12–19CrossRefPubMed Berg D, Behnke S, Walter U (2006) Application of transcranial sonography in extrapyramidal disorders: updated recommendations. Ultraschall Med 27(1):12–19CrossRefPubMed
18.
go back to reference Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D (2007) Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 33(1):15–25CrossRefPubMed Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D (2007) Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 33(1):15–25CrossRefPubMed
19.
go back to reference Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F (1994) Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 9(1):76–83CrossRefPubMed Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F (1994) Unified Parkinson’s Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 9(1):76–83CrossRefPubMed
20.
go back to reference Louis ED, Luchsinger JA, Tang MX, Mayeux R (2003) Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology 61(1):24–28CrossRefPubMed Louis ED, Luchsinger JA, Tang MX, Mayeux R (2003) Parkinsonian signs in older people: prevalence and associations with smoking and coffee. Neurology 61(1):24–28CrossRefPubMed
21.
go back to reference Louis ED, Tang MX, Mayeux R (2004) Parkinsonian signs in older people in a community-based study: risk of incident dementia. Arch Neurol 61(8):1273–1276CrossRefPubMed Louis ED, Tang MX, Mayeux R (2004) Parkinsonian signs in older people in a community-based study: risk of incident dementia. Arch Neurol 61(8):1273–1276CrossRefPubMed
22.
go back to reference Hummel T, Konnerth CG, Rosenheim K, Kobal G (2001) Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss. Ann Otol Rhinol Laryngol 110(10):976–981CrossRefPubMed Hummel T, Konnerth CG, Rosenheim K, Kobal G (2001) Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss. Ann Otol Rhinol Laryngol 110(10):976–981CrossRefPubMed
23.
go back to reference Gonera EG, van’t Hof M, Berger HJ, van Weel C, Horstink MW (1997) Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 12:871–876CrossRefPubMed Gonera EG, van’t Hof M, Berger HJ, van Weel C, Horstink MW (1997) Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 12:871–876CrossRefPubMed
24.
go back to reference Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:414–418CrossRefPubMed Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 18:414–418CrossRefPubMed
25.
go back to reference Ford B (2010) Pain in Parkinson’s disease. Mov Disord 25 (Suppl 1):S98–S103CrossRef Ford B (2010) Pain in Parkinson’s disease. Mov Disord 25 (Suppl 1):S98–S103CrossRef
26.
go back to reference Ehrt U, Larsen JP, Aarsland D (2009) Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry 17:269–275CrossRefPubMed Ehrt U, Larsen JP, Aarsland D (2009) Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry 17:269–275CrossRefPubMed
27.
go back to reference Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord 26(4):653–658PubMedCentralCrossRefPubMed Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D (2011) The patients’ perception of prodromal symptoms before the initial diagnosis of Parkinson’s disease. Mov Disord 26(4):653–658PubMedCentralCrossRefPubMed
28.
go back to reference Kurz M, Alves G, Aarsland D, Larsen JP (2003) Familial Parkinson’s disease: a community-based study. Eur J Neurol 10(2):159–163CrossRefPubMed Kurz M, Alves G, Aarsland D, Larsen JP (2003) Familial Parkinson’s disease: a community-based study. Eur J Neurol 10(2):159–163CrossRefPubMed
29.
go back to reference Ruprecht-Dorfler P, Berg D, Tucha O et al (2003) Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. Neuroimage 18(2):416–422CrossRefPubMed Ruprecht-Dorfler P, Berg D, Tucha O et al (2003) Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease. Neuroimage 18(2):416–422CrossRefPubMed
30.
go back to reference Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY (2012) How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135 (Pt 6):1860–1870CrossRef Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY (2012) How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 135 (Pt 6):1860–1870CrossRef
31.
go back to reference Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56(2):173–181CrossRefPubMed Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56(2):173–181CrossRefPubMed
32.
go back to reference Jost WH (1997) Gastrointestinal motility problems in patients with Parkinson’s disease—Effects of antiparkinsonian treatment and guidelines for management. Drug Aging 10(4):249–258CrossRef Jost WH (1997) Gastrointestinal motility problems in patients with Parkinson’s disease—Effects of antiparkinsonian treatment and guidelines for management. Drug Aging 10(4):249–258CrossRef
33.
go back to reference Abbott RD, Petrovitch H, White LR et al (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57(3):456–462CrossRefPubMed Abbott RD, Petrovitch H, White LR et al (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57(3):456–462CrossRefPubMed
34.
go back to reference Korczyn AD (1990) Autonomic nervous system disturbances in Parkinson’s disease. Adv Neurol 53:463–468PubMed Korczyn AD (1990) Autonomic nervous system disturbances in Parkinson’s disease. Adv Neurol 53:463–468PubMed
35.
36.
go back to reference Copeland JR, Beekman AT, Braam AW et al (2004) Depression among older people in Europe: the EURODEP studies. World Psychiatry 3(1):45–49PubMedCentralPubMed Copeland JR, Beekman AT, Braam AW et al (2004) Depression among older people in Europe: the EURODEP studies. World Psychiatry 3(1):45–49PubMedCentralPubMed
37.
go back to reference Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR (2012) Pre-motor features of Parkinson’s disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 18 (Suppl 1):S199–S202CrossRef Ross GW, Abbott RD, Petrovitch H, Tanner CM, White LR (2012) Pre-motor features of Parkinson’s disease: the Honolulu-Asia Aging Study experience. Parkinsonism Relat Disord 18 (Suppl 1):S199–S202CrossRef
38.
go back to reference Siderowf A, Jennings D, Eberly S et al (2012) Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 27(3):406–412CrossRefPubMed Siderowf A, Jennings D, Eberly S et al (2012) Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord 27(3):406–412CrossRefPubMed
39.
go back to reference Liepelt I, Behnke S, Schweitzer K et al (2011) Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging 32(9):1599–1606CrossRefPubMed Liepelt I, Behnke S, Schweitzer K et al (2011) Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. Neurobiol Aging 32(9):1599–1606CrossRefPubMed
40.
go back to reference Berg D, Godau J, Seppi K et al (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20(1):102–108CrossRefPubMed Berg D, Godau J, Seppi K et al (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20(1):102–108CrossRefPubMed
Metadata
Title
Risk factors and prodromal markers and the development of Parkinson’s disease
Authors
Stefanie Lerche
Klaus Seppi
Stefanie Behnke
Inga Liepelt-Scarfone
Jana Godau
Philipp Mahlknecht
Alexandra Gaenslen
Kathrin Brockmann
Karin Srulijes
Heiko Huber
Isabel Wurster
Heike Stockner
Stefan Kiechl
Johann Willeit
Arno Gasperi
Klaus Fassbender
Werner Poewe
Daniela Berg
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 1/2014
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-013-7171-0

Other articles of this Issue 1/2014

Journal of Neurology 1/2014 Go to the issue